Testing treatment planning to help eradicate rare advanced cancers
Part of Cancer clinical trials.
This trial looks at a more tailored way to choose treatment for people with rare cancers that have spread or grown locally and can’t be cured with standard therapies. The goal is to better target the tumor to improve the chance of tumor shrinkage or eradication.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a rare cancer (or a rare subtype of a more common cancer)
- Your cancer is advanced (metastatic and/or locally advanced)
- There is no curative (curing) treatment option for your situation
- Your cancer team believes you need systemic therapy (treatment that works through the body)
- You can understand and sign the consent forms, using written and oral information
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial compares treatment based on a detailed analysis of your tumor's genes (genome and transcriptome) with standard care. It aims to find better treatment options for people with advanced rare cancers that have not responded to previous therapy.
This study collects evidence on personalized (“targeted”) cancer treatments for adults with rare cancers or rare tumor changes. If you may qualify, it may help make these treatments more widely available in the future by studying how well they work and how patients feel.
This trial tests if growing a patient's tumor cells in the lab (organoids) and analyzing their genes can help doctors choose more effective treatments for rare cancers. You might be eligible if you have an advanced rare solid tumor and can provide fresh or stored tumor tissue for testing.
This study uses advanced testing (molecular profiling and imaging) to better understand cancers and help guide treatment. It is for people with certain advanced cancers who have not yet had immunotherapy or targeted therapy.
This study tests targeted drugs or immunotherapy based on the genetic features of your tumor. It may help people with rare, advanced cancers whose disease has progressed after standard treatment options.
This study creates a unique treatment plan based on the genetic changes found in your tumor. A team of experts will review your cancer's molecular profile to decide the best next therapy for you, even if standard options are not clear.
Hear when a new Multiomics trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.